Trial Profile

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone; Prednisone
Indications Prostate cancer
Focus Therapeutic Use
Acronyms FORMULA-509

Most Recent Events

13 May 2024 Planned primary completion date changed from 31 Dec 2023 to 5 Apr 2025.
27 Jan 2024 Results of Patient-reported health-related quality of life , presented at the 2024 Genitourinary Cancers Symposium
18 Feb 2023 Primary endpoint (PSA Progression Free Survival) has not been met, as per results presented at the 2023 Genitourinary Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com